Index

Note: Page numbers of article titles are in **boldface** type.

A

Antiviral therapy
  for chronic HBV infection
    direct antiviral therapy, 415–420
      impact on HCC development, 416–419
      impact on hepatic fibrosis, 415–416
      impact on liver disease progression, decompensation, and survival, 416
    HBsAg seroclearance as ideal outcome in, 420
    IFN-based, 414–415
    for end-stage HBV liver disease, 453–456

C

Cirrhosis
  HBV
    decompensated
      treatment of, 451–473
    in HCC, 385–389. See also Hepatocellular carcinoma (HCC), HBV infection in,
      treatment algorithms in, in patients with cirrhosis
        decompensated
          treatment of, **451–473**

E

Entecavir
  for chronic HBV infection
    long-term results of, 447–448

H

HBsAg. See Hepatitis B surface antigen (HBsAg)
HBV infection. See Hepatitis B virus (HBV) infection
HCC. See Hepatocellular carcinoma (HCC)
HDV. See Hepatitis D virus (HDV)
Hepatitis B surface antigen (HBsAg)
  quantification of
    in predicting natural history and treatment outcome in chronic HBV patients, **399–412**
      add on therapy, 407
      clinical applications of, 400
      described, 400–401
      HDV, 407
      natural history, 401–403
Hepatitis (continued)
nucleos(t)ides analogues, 405–407
reasons for, 399–400
treatment, 403–405

Hepatitis B virus (HBV) cirrhosis
decompensated
treatment of, 451–473
introduction, 451–452
natural history of, 452–453

Hepatitis B virus (HBV) infection
chronic
described, 425–426
introduction, 413–414

long-term outcome of
therapy effects on, 413–423
described, 414
direct antiviral therapy, 415–420
IFN-based therapy, 414–415
introduction, 413–414
perspectives on, 420

natural history and treatment outcome in
HBsAg quantification in prediction of, 399–412. See also Hepatitis B surface
antigen (HBsAg), quantification of
treatment of
decision to treat, 446
improved efficacy in, 446
nucleos(t)ide analogues in, 445–450. See also Nucleos(t)ide analogues, for
chronic HBV infection
objective of, 445–446
PegIFN in, 425–443. See also Pegylated interferon (PegIFN), for chronic HBV
infection, results of
in HCC, 375–397. See also Hepatocellular carcinoma (HCC), HBV infection in
in HIV–infected patients, 489–501. See also HIV–infected patients, HBV infection in

Hepatitis B virus (HBV) liver disease
end-stage
antiviral therapy of, 453–456
treatment of
liver transplantation in, 456–467. See also Liver transplantation

Hepatitis D virus (HDV)
biology of, 475–476
in drug addicts in U.S., 482–483
epidemiology of
current perception of, 476–477
in Europe, 477–478
outside Europe, 478–482
current scenario, 479–482
endemicity in Africa and Asia, 479–482
outbreaks of HDV, 479
in 1980s to 1990s, 478–479
HBsAg quantification in, 407
introduction, 475–477
Hepatitis D virus (HDV) infection
  in HIV–HBV coinfected patients, 496
Hepatitis delta. See Hepatitis D virus (HDV)
Hepatocellular carcinoma (HCC)
  direct antiviral therapy for chronic HBV infection effects on, 416–419
HBV infection in, 375–397
  diagnosis of
    early, 380–383
  epidemiology of, 376
  introduction, 375–376
  natural history of tumor in, 379–380
  pathogenesis of, 378–379
  primary prevention of, 389–391
  risk factors for, 376–378
  screening for
    cost–usefulness ratio of, 383–384
    treatment algorithms in, 385–389
    in patients with cirrhosis, 385–389
      advanced HCC, 388
      assessment of tumor response, 389
      end-stage HCC, 389
      intermediate HCC, 388
      very early/early HCC, 385–388
    in patients with noncirrhotic liver, 385
    tumor prognostication in, 384
HIV–infected patients
  HBV infection in, 489–501
    clinical outcome of, 490–491
    diagnosis of, 491–492
    epidemiology of, 489–490
  HDV infection with, 496
  treatment of, 492–495
  vaccination for, 495–496

I
Interferon(s)
  pegylated. See Pegylated interferon (PegIFN)
Interferon-α (IFN)
  for chronic HBV infection
    effect on long-term outcomes, 414–415

L
Liver disease
  HBV
    end-stage
      antiviral therapy for, 453–456
Liver transplant patients
  treatment of, 451–473
Liver transplantation
  HBV recurrence after, 466–467
Liver (continued)
  diagnosis, mechanisms, and risk factors for, 457–458
  posttransplant prevention of, 458–466
    combination prophylaxis in, 458–461
    future prospects for, 464–466
    guidelines for, 464–466
  HBIG-free prophylactic regimens in, 464
  prophylaxis protocols with minimization of HBIG in, 461–464
  indications for, 456–457
  results of, 456–457

N
Nucleos(t)ide analogues
  for chronic HBV infection
    described, 447
    long-term results of, 445–450
      entecavir, 447–448
      tenofovir, 447–448
    in outcome prediction, 405–407

P
Pegylated interferon (PegIFN)
  adverse effects of, 427–428
  for chronic HBV infection
    results of, 425–443
      alpha interferons: mechanisms of action of, 426–427
      introduction, 425–426
    for HBeAg-negative patients, 433–439
    for HBeAg-positive patients, 428–432
    in NUC responders, 439
    pharmacology of, 426–427

T
Tenofovir
  for chronic HBV infection
    long-term results of, 447–448

V
Vaccination
  for HBV infection in HIV–infected patients, 495–496